Biohit Oyj (HEL:BIOBV)

Market Cap	43.57M
Revenue (ttm)	14.28M
Net Income (ttm)	2.27M
Shares Out	15.18M
EPS (ttm)	0.15
PE Ratio	19.21
Forward PE	17.94
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,637
Average Volume	12,287
Open	2.930
Previous Close	2.850
Day's Range	2.810 - 2.930
52-Week Range	2.080 - 4.350
Beta	0.59
RSI	45.20
Earnings Date	Aug 6, 2025

About Biohit Oyj

Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company’s diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist clinicians and general practitioner; BIOHIT Active B12, a test for measuring the concentration of total vitamin-B12 in the serum; BIOHIT Total 25OH Vit...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 46
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: BIOBV

Financial Performance

In 2024, Biohit Oyj's revenue was 14.28 million, an increase of 9.23% compared to the previous year's 13.08 million. Earnings were 2.57 million, an increase of 38.74%.